Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used ...

Personalis (NASDAQ:PSNL) executives on the company’s fourth quarter 2025 earnings call highlighted accelerating clinical adoption of its ultra-sensitive NeXT Personal minimal residual disease (MRD) ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-p ...

Former Neighbours great Ian Smith is preparing to mark an extraordinary milestone after defying incredible odds.

Tech tycoons, podcast bros and Hollywood stars are all piling money into full-body scans, which deploy AI in the hope of catching everything from high cholesterol to cancer. Is this the first step to ...

In Colorado, as of 2025, about 500 people a year die from lung cancer as the result of radon gas exposure. Nationally, the number of lung cancer deaths attributed to radon is about 21,000 per year.

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.